Corcept Therapeutics Inc CORT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)
-
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
-
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
-
20 companies screened for quality in a cheap part of the stock market
-
20 companies screened for quality in a cheap -2-
-
20 companies screened for quality in a cheap part of the stock market
-
20 companies screened for quality in a cheap -2-
-
Corcept Therapeutics Shares Slide Premarket on Loss in Teva Patent Suit
Trading Information
- Previous Close Price
- $43.28
- Day Range
- $42.81–44.02
- 52-Week Range
- $20.84–44.37
- Bid/Ask
- $41.96 / $46.00
- Market Cap
- $4.59 Bil
- Volume/Avg
- 625,818 / 849,984
Key Statistics
- Price/Earnings (Normalized)
- 54.23
- Price/Sales
- 8.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 352
- Website
- https://www.corcept.com
Comparables
Valuation
|
Metric
|
CORT
|
FULC
|
TERN
|
|---|---|---|---|
Price/Earnings (Normalized) | 54.23 | — | — |
Price/Book Value | 7.69 | 0.86 | 2.75 |
Price/Sales | 8.54 | 2.90 | — |
Price/Cash Flow | 35.76 | — | — |
Price/Earnings
CORT
FULC
TERN
Financial Strength
|
Metric
|
CORT
|
FULC
|
TERN
|
|---|---|---|---|
Quick Ratio | 5.23 | 21.84 | 20.57 |
Current Ratio | 5.57 | 22.07 | 21.02 |
Interest Coverage | — | — | — |
Quick Ratio
CORT
FULC
TERN
Profitability
|
Metric
|
CORT
|
FULC
|
TERN
|
|---|---|---|---|
Return on Assets (Normalized) | 27.60% | −1.76% | −28.87% |
Return on Equity (Normalized) | 33.89% | −1.91% | −30.36% |
Return on Invested Capital (Normalized) | 30.18% | −1.83% | −34.37% |
Return on Assets
CORT
FULC
TERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wrvhvlgvxs | Srbv | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lhmxlfxv | Vjngz | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lmvbscv | Grncp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pmhqgymwh | Vywljcr | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Svlckqtc | Ltwx | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ngxtznfkb | Fcdr | $28.1 Bil | |||
| Moderna Inc
MRNA
| Spxcpfvs | Rnx | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Xjrdmkwm | Bmbbv | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fctzjwdlf | Stvpsth | $13.4 Bil | |||
| Incyte Corp
INCY
| Swvzcln | Scncgzk | $12.7 Bil |
United States